Bone tumors can cause symptoms such as persistent pain and unintended weight loss, or they might only be discovered when ...
Pasatru is the first and only FDA-approved treatment demonstrating reductions in both new HO lesions and clinician-assessed flare-ups, per ...
Asianet Newsable on MSN
Regeneron’s rare disease drug shows zero new abnormal bone growth in extended trial – REGN stock heads for best day in over a month
The firm’s Pasatru drug was approved by the FDA in August, after trial results showed at least a 90% reduction in new ...
Regeneron Pharmaceuticals, Inc. ( REGN) reported positive 84-week results from the Phase 3 OPTIMA trial, showing that Pasatru (garetosmab-grts) prevented the formation of new heterotopic ossification ...
A head-to-head study of 108 prostate cancer patients shows gallium-68 PSMA PET/CT detects bone metastases far more accurately ...
Researchers built a two-stage, biomimetically inspired AI pipeline that detects primary bone tumors on X-rays while ...
A team of researchers from the Translational Oncology Research Centre (TORC) of Vrije Universiteit Brussel (VUB), in collaboration with leading German universities, has developed a new biomaterial ...
A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients. The findings showcase a ...
The team tackled a critical challenge in treating multiple myeloma-a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients. These ...
The bone metastasis in solid tumors market is expected to evolve significantly over the forecast period, driven by rising cancer incidence, improved survival rates, increasing prevalence of metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results